MagnetisMM-32: A Study to Learn About the Study Medicine Called Elranatamab in People With Multiple Myeloma (MM) That Has Come Back After Taking Other Treatments (Including Prior Treatment With an Anti-CD38 Antibody and Lenalidomide)
Conditions: Multiple Myeloma Interventions: Drug: Elranatamab; Drug: Elotuzumab; Drug: Pomalidomide; Drug: Dexamethasone; Drug: Bortezomib; Drug: Carfilzomib Sponsors: Pfizer Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - November 30, 2023 Category: Research Source Type: clinical trials
Evaluating the Uptake and Utility of Clinical Pathways for Newly Diagnosed Patients With Multiple Myeloma
Conditions: Multiple Myeloma; Multiple Myeloma Without Mention of Remission Interventions: Other: Multiple Myeloma Pathway; Other: All4Cure Platform; Other: Documentation Pathway Sponsors: All4Cure; Janssen Scientific Affairs, LLC Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - November 29, 2023 Category: Research Source Type: clinical trials
Remote Monitoring With Health-Coaching to Improve Quality of Life in Older Patients With Multiple Myeloma
Conditions: Multiple Myeloma Interventions: Behavioral: Supportive Care (home-based physical activity); Other: Exercise Intervention; Other: telephone interview; Other: Remote Monitoring; Procedure: Patient Monitoring; Other: Questionnaire Administration Sponsors: Mayo Clinic Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - November 24, 2023 Category: Research Source Type: clinical trials
Daratumumab and Carfilzomib-based Induction/Consolidation/Maintenance Therapy in Ultra High-risk Multiple Myeloma
Conditions: Multiple Myeloma; Primary Plasma Cell Leukemia; Extramedullary Multiple Myeloma Interventions: Drug: Daratumumab; Drug: Carfilzomib; Drug: Lenalidomide; Drug: Dexamethasone; Drug: Cisplatin; Drug: epirubicin; Drug: Cyclophosphamide; Drug: Etoposide; Drug: Melphalan; Procedure: ASCT; Drug: bortezomib Sponsors: Wuhan Union Hospital, China Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - November 21, 2023 Category: Research Source Type: clinical trials
Pilot Study Dara-CyBorD in Newly Diagnosed Multiple Myeloma Patients With Renal Failure
Conditions: Multiple Myeloma; Renal Failure Interventions: Combination Product: Daratumumab-hyaluronidase in Combination with Bortezomib, Cyclophosphamide, and Dexamethasone Sponsors: Augusta University Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - November 21, 2023 Category: Research Source Type: clinical trials
A Proof-of-concept Study to Learn Whether Linvoseltamab Can Prevent Multiple Myeloma in Adult Patients With High-Risk Monoclonal Gammopathy of Undetermined Significance or Non-High-Risk Smoldering Multiple Myeloma
Conditions: Monoclonal Gammopathy of Undetermined Significance (MGUS); Smoldering Multiple Myeloma (SMM) Interventions: Drug: Linvoseltamab Sponsors: Regeneron Pharmaceuticals Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - November 20, 2023 Category: Research Source Type: clinical trials
Elranatamab in R/R Multiple Myeloma
Conditions: Refractory Multiple Myeloma; Relapse Multiple Myeloma; Multiple Myeloma Interventions: Drug: Elranatamab Sponsors: Massachusetts General Hospital; Pfizer Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - November 18, 2023 Category: Research Source Type: clinical trials
Evaluation of the Role of Connected Scales in the Therapeutic Care of Hematology Patients
Conditions: Lymphoma, Non-Hodgkin; Myeloma Multiple Interventions: Device: Connected scale " Body Comp Pro " from Withings Sponsors: Assistance Publique - H ôpitaux de Paris; Withings Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - November 15, 2023 Category: Research Source Type: clinical trials
Safety and Efficacy of APRIL-BAFF-Bicephali CAR-T in Relapsed, Refractory Multiple Myeloma
Conditions: Multiple Myeloma Interventions: Other: APRIL-BAFF-Bicephali CAR-T cells Sponsors: Xuzhou Medical University; Yake Biotechnology Ltd. Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - November 15, 2023 Category: Research Source Type: clinical trials
A Study of CM313 in Subjects With Relapsed or Refractory Multiple Myeloma
Conditions: Multiple Myeloma Interventions: Biological: CM313 injection Sponsors: Keymed Biosciences Co.Ltd Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - November 10, 2023 Category: Research Source Type: clinical trials
A Study to Identify Barriers to Cellular Therapies for People With Plasma Cell Disorders
Conditions: Multiple Myeloma Interventions: Other: Lecture on the role of cellular therapies in relapse/refractory multiple myeloma/RRMM; Behavioral: Hospital Anxiety and Depression Scale; Behavioral: Duke-UNC Functional Social Support Questionnaire; Behavioral: Distress Thermometer; Behavioral: FACT-BMT; Behavioral: Psychosocial Assessments of Candidates for Transplantation Sponsors: Memorial Sloan Kettering Cancer Center Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - November 10, 2023 Category: Research Source Type: clinical trials
A Study to Evaluate the Safety, Effectiveness and Tolerable Dose of BMS-986393 in Novel Combinations in Participants With Relapsed and/or Refractory Multiple Myeloma
Conditions: Multiple Myeloma Interventions: Drug: BMS-986393; Drug: Alnuctamab; Drug: Mezigdomide; Drug: Iberdomide Sponsors: Juno Therapeutics, Inc., a Bristol-Myers Squibb Company Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - November 8, 2023 Category: Research Source Type: clinical trials
IDP-023 as a Single Agent and in Combination With Antibody Therapies in Patients With Advanced Hematologic Cancers
Conditions: NHL; Multiple Myeloma; Blood Cancer; Refractory Non-Hodgkin Lymphoma; Relapsed Non-Hodgkin Lymphoma; Refractory Multiple Myeloma; Relapsed Multiple Myeloma Interventions: Drug: IDP-023; Drug: Rituximab; Drug: Daratumumab; Drug: Interleukin-2; Drug: Cyclophosphamide; Drug: Fludarabine; Drug: Mesna Sponsors: Indapta Therapeutics, INC. Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - November 7, 2023 Category: Research Source Type: clinical trials
Lapelga vs Gastrofil
Conditions: Multiple Myeloma; Lymphoma; Engagement, Patient; Febrile Neutropenia Interventions: Drug: Grastofil ®; Drug: Lapelga Sponsors: Lawson Health Research Institute; Apobiologix. Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - November 3, 2023 Category: Research Source Type: clinical trials
A Study of Venetoclax in Combination With Isatuximab and Dexamethasone for Relapsed/Refractory Multiple Myeloma
Conditions: Multiple Myeloma in Relapse; Multiple Myeloma, Refractory Interventions: Drug: Venetoclax Sponsors: Oncotherapeutics Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - November 2, 2023 Category: Research Source Type: clinical trials
